Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kovanaze vs. Articaine for Maxillary Pulpal Anesthesia
NCT03962634Phase 2
Key facts
- Status
- Terminated
- Start
- Aug 2019
- Primary completion
- Sep 2019
- Countries
- 1
- Sponsor
- Virginia Commonwealth University
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Conditions
- dental cariesapical periodontitis (AP)
01
Overview
Phase 2, randomised trial of tetracaine HCl + oxymetazoline HCl in dental caries and apical periodontitis (AP), sponsored by Virginia Commonwealth University. Primary endpoint: Success Rate of Pulpal Anesthesia at 3 hours. Started Aug 2019; status: terminated.
02
Design
- Study design
- Randomized
03
Who it enrols
Children >20kg and adults requiring maxillary dental procedures with specific cardiovascular and nasal health criteria.
04
Endpoints
Primary
Success Rate of Pulpal Anesthesia
Beyond the preview
Go deeper on NCT03962634.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962634.